Immtech Announces Interim Analysis In Phase III African Sleeping Sickness Trial
Oct 5th 2007Drug InformationClinical Trials
Immtech Pharmaceuticals, Inc. (Amex: IMM) announced the completion of interim analysis of itsPhase III pivotal clinical trial of Immtech’s oral drug candidate, pafuramidine. An independent Data Safety Monitoring Board (DSMB) conducted the interim analysis and recommended that the trial should continue as planned. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
